Károly Jambrovics

Dr. Károly Jambrovics

University of Debrecen, Biochemistry and Molecular biology Department Medical faculty

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2012 in Annals of Botany
Verified
Journal Article
Open access
PDF file
DBDániel Beyer
Dániel Beyer
ITIldikó Tándor
Ildikó Tándor
Zoltan KonyaZoltan Konya
Zoltan Konya
RBRobert Batori
Robert Batori
Jason RoszikJason Roszik
Jason Roszik
Csaba MatheCsaba Mathe
Csaba Mathe
Microcystin-LR (MCY-LR) is a cyanobacterial toxin, a specific inhibitor of type 1 and 2A protein phosphatases (PP1 and PP2A) with significant impact on aquatic ecosystems. It has the potential to alter regulation of the plant cell cycle. The aim of this study was improved understanding of the mitotic alterations induced by cyanotoxin in Vicia faba, a model organism for plant cell biology studies. Vicia faba seedlings were treated over the long and short term with MCY-LR purified in our laboratory. Short-term treatments were performed on root meristems synchronized with hydroxylurea. Sections of lateral root tips were labelled for chromatin, phosphorylated histone H3 and β-tubulin via histochemical and immunohistochemical methods. Mitotic activity and the occurrence of mitotic alterations were detected and analysed by fluorescence microscopy. The phosphorylation state of histone H3 was studied by Western blotting. Long-term MCY-LR exposure of lateral root tip meristems increased the percentage of either early or late mitosis in a concentration-dependent manner. We observed hypercondensed chromosomes and altered sister chromatid segregation (lagging chromosomes) leading to the formation of micronuclei, accompanied by the formation of disrupted, multipolar and monopolar spindles, disrupted phragmoplasts and the hyperphosphorylation of histone H3 at Ser10. Short-term MCY-LR treatment of synchronized cells showed that PP1 and PP2A inhibition delayed the onset of anaphase at 1 µg mL−1 MCY-LR, accelerated cell cycle at 10 µg mL−1 MCY-LR and induced the formation of lagging chromosomes. In this case mitotic microtubule alterations were not detected, but histone H3 was hyperphosphorylated. MCY-LR delayed metaphase–anaphase transition. Consequently, it induced aberrant chromatid segregation and micronucleus formation that could be associated with both H3 hyperphosphorylation and altered microtubule organization. However, these two phenomena seemed to be independent. The toxin may be a useful tool in the study of plant cell cycle regulation.

11 March 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KJKároly Jambrovics
Károly Jambrovics
IUIván Péter Uray
Iván Péter Uray
Jeffrey KeillorJeffrey Keillor
Jeffrey Keillor
LFLászló Fésüs
László Fésüs
ZBZoltán Balajthy
Zoltán Balajthy
Randomized trials in acute promyelocytic leukemia patients have shown that treatment with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior in efficacy to monotherapy, with significantly decreased mortality. So far, there are little data available to explain the success of the ATRA and ATO combination treatment in molecular terms. We showed that ATRA- and ATO-treated cells had the same capacity for superoxide production, which was reduced by two-thirds in the combined treatment. Secreted inflammatory biomarkers (monocyte chemoattractant protein-1 [MCP-1], interleukin-1 beta [IL-1β] and tumor necrosis factor-α [TNF-α]) were significantly decreased and were further reduced in a transglutaminase 2 (TG2) expression-dependent manner. The amount of secreted TNF-α in the supernatant of NB4 TG2 knockout cells was close to 50 times lower than in ATRA-treated differentiated wild-type NB4 cells. The irreversible inhibitor of TG2 NC9 not only decreased reactive oxygen species production 28-fold, but decreased the concentration of MCP-1, IL-1β and TNF-α 8-, 15- and 61-fold, respectively in the combined ATRA + ATO-treated wild-type NB4 cell culture. We propose that atypical expression of TG2 leads to the generation of inflammation, which thereby serves as a potential target for the prevention of differentiation syndrome.

Verified
Journal Article
Open access
PDF file
KJKároly Jambrovics
Károly Jambrovics
Szilárd PóliskaSzilárd Póliska
Szilárd Póliska
BSBeáta Scholtz
Beáta Scholtz
IUIván Péter Uray
Iván Péter Uray
ZBZoltán Balajthy
Zoltán Balajthy
Transglutaminase 2 (TG2) is a critical cancer cell survival factor that activates several signalling pathways to foster drug resistance, cancer stem cell survival, metastasis, inflammation, epithelial-mesenchymal transition, and angiogenesis. All-trans retinoic acid (ATRA) and chemotherapy have been the standard treatments for acute promyelocytic leukaemia (APL), but clinical studies have shown that arsenic trioxide (ATO), alone or in combination with ATRA, can improve outcomes. ATO exerts cytotoxic effects in a variety of ways by inducing oxidative stress, genotoxicity, altered signal transduction, and/or epigenetic modification. In the present study, we showed that ATO increased ROS production and apoptosis ratios in ATRA-differentiated NB4 leukaemia cells, and that these responses were enhanced when TG2 was deleted. The combined ATRA + ATO treatment also increased the amount of nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor, an adaptive regulator of the cellular oxidative stress response, and calpain proteolytic activity, resulting in TG2 degradation and the reduced survival of WT leukaemia cells. We further showed that the induced TG2 protein expression was degraded in the MCF-7 epithelial cell line and primary peripheral blood mononuclear cells upon ATO treatment, thereby sensitising these cell types to apoptotic signals.

3 November 2025 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
KJKároly Jambrovics
Károly Jambrovics
WAWedean Al-Hadban
Wedean Al-Hadban
AMAnett Mázló-Türk
Anett Mázló-Türk
ISIstvan Szatmari
Istvan Szatmari
BDBoglárka Dobó
Boglárka Dobó
ZBZoltán Balajthy
Zoltán Balajthy
Differentiation syndrome (DS) is a serious complication with an unclear pathogenesis that arises following all-trans retinoic acid (ATRA) or arsenic trioxide induction therapy in acute promyelocytic leukemia (APL). DS symptoms include pyrexia, respiratory compromise, increased body mass, fluid accumulation, pulmonary infiltrates, hypotension, tachycardia, edema, and sepsis. It can also affect the kidneys and the central nervous system. The standard treatment to counteract DS involves the temporary cessation of ATRA or arsenic trioxide treatment and the administration of high-dose steroids to mitigate the inflammatory response. If left untreated, DS can be fatal. Further research has revealed that the inability to promptly recognize intracranial hemorrhage (ICH) in patients with APL may result in lethal consequences, with the cytokine storm identified as the principal factor in this scenario as well. ATRA therapy is known to induce transglutaminase 2 (TG2), which functions as a catalyst for DS development. In this study, we used NB4 cell lines and cells from a human patient with APL to investigate the ex vivo effects of ATRA and 25(OH)D 3 cotreatment on NF-κB-regulated luciferase reporter gene activity. ATRA alone substantially enhanced cellular NF-κB luciferase reporter gene activity, whereas 25(OH)D 3 dose-dependently reduced this activity. During ATRA-initiated cell maturation, 25(OH)D 3 , known as calcidiol, suppressed the mRNA expression of NF-κB ( p65/p50 ) and Rel family members, as well as the expression of genes associated with increased NF-κB activity. 25(OH)D 3 also inhibited the ATRA-induced production of cytokines (e.g., IL-8), including IL-1β, TNF-α, and MCP-1, associated with the “cytokine storm.” Combined treatment with ATRA plus 25(OH)D 3 reduced cellular phospho-p65 and transglutaminase 2 (TG2) levels and increased the level of inhibitor of Rel (IκB), thereby attenuating the cytokine storm. These findings provide a molecular interpretation for clinical DS and IHC observations and may support future exploration of ATRA plus 25(OH)D 3 cotreatment as a therapy for APL.

12 May 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
KJKároly Jambrovics
Károly Jambrovics
Szilárd PóliskaSzilárd Póliska
Szilárd Póliska
BSBeáta Scholtz
Beáta Scholtz
IUIván Péter Uray
Iván Péter Uray
ZBZoltán Balajthy
Zoltán Balajthy
Transglutaminase 2 (TG2) is a critical cancer cell survival factor that activates several signaling pathways to foster drug resistance, cancer stem cell survival, metastasis, inflammation, epithelial mesenchymal transition, and angiogenesis. All-trans retinoic acid (ATRA) and chemotherapy have been the standard treatments for acute promyelocytic leukemia (APL), but clinical studies have shown that arsenic trioxide (ATO), alone or in combination with ATRA, can improve outcomes. ATO exerts cytotoxic effects in a variety of ways by inducing oxidative stress, genotoxicity, altered signal transduction, and/or epigenetic modification. In the present study, we showed that ATO increased ROS production and apoptosis ratios in ATRA-differentiated NB4 leukemia cells and that these responses were enhanced when TG2 was deleted. The combined ATRA+ATO treatment also increased the amount of nuclear factor erythroid 2-related factor 2 (NRF2) transcription factor, an adaptive regulator of cellular oxidative stress response, and proteolytic activity of calpain, resulting in TG2 degradation and reduced survival of WT leukemia cells. We further showed that upon ATO treatment, the induced TG2 protein expression was degraded in the MCF-7 epithelial cell line, and primary peripheral blood mononuclear cells, thereby sensitizing these cell types to apoptotic signals.